Scott Laurie

Scott Laurie

Université d'Ottawa - Ottawa / Canada
Others
AD Scientific Index ID: 4962797
University of Ottawa
person_outline Scott Laurie's MOST POPULAR ARTICLES
1-) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled … - K Park, EH Tan, K O\\\'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ...
2-) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study - MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ...
3-) American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer - DG Pfister, SA Laurie, GS Weinstein, WM Mendenhall, DJ Adelstein, ...
4-) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialL Paz-Ares, EH Tan, K O’Byrne, L Zhang, V Hirsh, M Boyer, JCH Yang, ...Annals of Oncology 28 (2), 270-277, 20175872017
5-) Nivolumab monotherapy for first-line treatment of advanced non–small-cell lung cancerS Gettinger, NA Rizvi, LQ Chow, H Borghaei, J Brahmer, N Ready, ...Journal of Clinical Oncology 34 (25), 2980-2987, 20165542016